WithdrawnNCT04811404
This study has public registry information. It focuses on bipolarity and currently lists study information in the United States.
BipolarityOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- New York State Psychiatric Institute
- Condition
- Bipolarity
TerminatedNCT03900754
This study has public registry information. It focuses on schizophrenia and currently lists study information in the United States.
SchizophreniaOtherFrom 18 Years to 70 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Schizophrenia
OngoingEUCTR 2004-002591-42
This study is ongoing in Spain. It is testing bifeprunox for Schizophrenia.
SchizophreniaOther
- Countries
- Spain
- Sponsor
- H.Lundbeck A/S
- Condition
- Schizophrenia
CompletedNCT01626859
This study is completed. It focuses on schizophrenia and currently lists study information in Japan.
SchizophreniaOtherFrom 20 Years to 64 Years
- Countries
- Japan
- Sponsor
- Tanabe Pharma Corporation
- Condition
- Schizophrenia
CompletedNCT02189057
This study is completed. It focuses on depression and currently lists study information in the United States.
Depression, BipolarityOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Mayo Clinic
- Condition
- Depression, Bipolarity
TerminatedNCT02827513
This study has public registry information in Australia. It focuses on ADHD.
ADHDOtherFrom 18 Years to 45 Years
- Countries
- Australia
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- ADHD
TerminatedNCT06673368
This study has public registry information in the United States. It focuses on ADHD.
ADHDOtherFrom 13 Years to 17 Years
- Countries
- United States
- Sponsor
- Neurocentria, Inc.
- Condition
- ADHD
OngoingEUCTR 2017-001739-38
This study is ongoing in the United Kingdom and in View results. It is testing Multiple Oral Doses of TAK-831 for Schizophrenia.
SchizophreniaOther
- Countries
- United Kingdom, View results
- Sponsor
- Takeda Development Centre Europe Ltd.
- Condition
- Schizophrenia
CompletedNCT04158687
This study is completed in the United States. It is testing Safety and Efficacy of CTP-692 for schizophrenia.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Concert Pharmaceuticals
- Condition
- Schizophrenia
CompletedEUCTR 2018-003825-27
This study is completed in the United Kingdom, in Germany, and in View results. It is testing Safety and Efficacy of BIIB104 for schizophrenia.
SchizophreniaOther
- Countries
- United Kingdom, Germany, View results
- Sponsor
- Biogen Idec Research Limited
- Condition
- Schizophrenia
Active Not RecruitingNCT06809595
This study is active but not recruiting in the United States, in France, in the United Kingdom, .... It focuses on anxiety.
AnxietyOtherFrom 18 Years to 74 Years
- Countries
- United States, France, United Kingdom, ...
- Sponsor
- Definium Therapeutics US, Inc.
- Condition
- Anxiety
Active Not RecruitingNCT06741228
This study is active but not recruiting in the United States. It focuses on anxiety.
AnxietyOtherFrom 18 Years to 74 Years
- Countries
- United States
- Sponsor
- Definium Therapeutics US, Inc.
- Condition
- Anxiety
